EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Mahsa Hoseinzadeh, Mohammad Javad Mokhtari iD, Farshid Kafilzadeh, Javad Mohammadnejad, Yaghoob Taheri

IET Nanobiotechnology · 2023

DOI: 10.1049/nbt2.12143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IET Nanobiotechnology, 2023. Verfasst von Mahsa Hoseinzadeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran. Hauptthemen laut MEDLINE: Nanoparticles, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)‐functionalised and alginate (Alg)‐modified poly lactic‐co‐glycolic acid (PLGA) nanocomposite was developed for delivery of doxorubicin (Dox) to HepG2 and Huh7 liver cancer cells. After synthesising the nanocarrier, several analytical devices, including FT‐IR, DLS, TGA, and TEM, were employed for its characterisation. Nano‐metric size (55 and 85 nm in diameter), close to neutral surface charge, semi‐spherical morphology, and successful synthesis were approved. Dox entrapment efficiency was determined near 1%, and sustained and pH‐sensitive drug release behaviours of nanocarrier were ascertained for DDS. Afterwards, the cell viability test was carried out to study the HepG2 and Huh7 cells suppression capability of FA‐PLGA‐Dox‐Alg. About 12% and 10% cell viabilities were observed in HepG2 and Huh7 cancer cells after 24 h treatment with 400 nM concentration of FA‐PLGA‐Dox‐Alg nanocarrier respectively. The IC 50 value was observed for 100 nM after 24 h of treatment in cancer cells. These data have indicated that fabricated nanocarrier could be promising DDS against liver cancer and replace with conventional approaches in cancer treatment, like chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLiver NeoplasmsHumansPolylactic Acid-Polyglycolic Acid CopolymerPolyglycolic AcidGlycolsLactic AcidAlginatesSpectroscopy, Fourier Transform InfraredDrug Delivery SystemsDoxorubicinDrug CarriersDrug LiberationGlycolates

Stichwörter der Autor:innen

cancerdrug delivery systemsnanocomposites

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerPolyglycolic AcidGlycolsLactic AcidAlginatesDoxorubicinDrug Carriersglycolic acidGlycolates

Autor:innen und Institutionen

  • Department of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
  • Department of Biology, Zarghan Branch, Islamic Azad University, Zarghan, Iran.
  • Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran.

ORCID-Profile: Mohammad Javad Mokhtari

Zitieren

APA

Hoseinzadeh, M., Mokhtari, M. J., Kafilzadeh, F., Mohammadnejad, J., & Taheri, Y. (2023). Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells. IET Nanobiotechnology. https://doi.org/10.1049/nbt2.12143

Vancouver

Hoseinzadeh M, Mokhtari MJ, Kafilzadeh F, Mohammadnejad J, Taheri Y. Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells. IET Nanobiotechnology. 2023. doi:10.1049/nbt2.12143

BibTeX
@article{Hoseinzadeh2023,
  author = {Hoseinzadeh, Mahsa and Mokhtari, Mohammad Javad and Kafilzadeh, Farshid and Mohammadnejad, Javad and Taheri, Yaghoob},
  title = {Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells},
  journal = {IET Nanobiotechnology},
  year = {2023},
  doi = {10.1049/nbt2.12143}
}
Kostenlos starten →